Without Biannual Time Shift, Prevalence of Obesity, Stroke May Be Reduced
via HealthDayWEDNESDAY, Sept. 17, 2025 -- The prevalence of obesity and stroke would be reduced with permanent Standard Time (SDT) and Daylight Saving Time (DST) compared with the current Biannual Shifting (BAS) in the United States, according to a study published online Sept. 15 in the Proceedings of the National Academy of Sciences.
Lara Weed and Jamie M. Zeitzer, Ph.D., from Stanford University in California, estimated the impact of permanent SDT or DST on health by modeling the circadian impact of SDT, DST, and BAS across a year in the United States.
The researchers found that compared with either permanent SDT or DST, BAS produces a greater burden on the circadian system, with chronotype and location (latitude and location within time zones) affecting the burden. There would be a decrease in the prevalence of obesity and stroke under SDT compared with the current policy under idealized light exposure conditions and after controlling for health and socioeconomic factors (−0.78 and −0.09 percent, respectively). Furthermore, there would be decreases in the prevalence of obesity and stroke under permanent DST, although to a lesser extent (−0.51 and −0.07 percent, respectively).
"We found that staying in Standard Time or staying in Daylight Saving Time is definitely better than switching twice a year," Zeitzer said in a statement.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-09-18 16:18
Read more
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions